Plato Investment Management Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Plato Investment Management Ltd significantly increased its stake in Regeneron Pharmaceuticals by 41.9% during the first quarter, bringing their total holdings to 3,777 shares valued at approximately $2.42 million.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, surpassing expectations and reflecting a revenue increase of 3.6% year-over-year.
• The company has received positive ratings from several analysts, with a current consensus rating of "Moderate Buy" and an average price target of $817.67.

Plato Investment Management Ltd raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 41.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,777 shares of the biopharmaceutical company's stock after acquiring an additional 1,116 shares during the period. Plato Investment Management Ltd's holdings in Regeneron Pharmaceuticals were worth $2,421,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Marietta Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 30.2% during the first quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after acquiring an additional 2,501 shares during the last quarter. GAMMA Investing LLC grew its position in Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Regeneron Pharmaceuticals by 3.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the last quarter. KBC Group NV grew its position in Regeneron Pharmaceuticals by 9.4% during the first quarter. KBC Group NV now owns 149,440 shares of the biopharmaceutical company's stock valued at $94,779,000 after acquiring an additional 12,793 shares during the last quarter. Finally, Lmcg Investments LLC grew its position in Regeneron Pharmaceuticals by 231.3% during the first quarter. Lmcg Investments LLC now owns 14,481 shares of the biopharmaceutical company's stock valued at $9,184,000 after acquiring an additional 10,110 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Sanford C. Bernstein raised their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Jefferies Financial Group raised their target price on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a "buy" rating in a report on Wednesday, August 27th. Canaccord Genuity Group restated a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $555.83 on Thursday. The stock has a market cap of $58.91 billion, a P/E ratio of 14.01, a price-to-earnings-growth ratio of 1.86 and a beta of 0.35. The firm's fifty day simple moving average is $563.85 and its 200 day simple moving average is $581.78. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,170.58. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $11.56 earnings per share. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.